

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



ADULT MEDICATION GUIDELINE

Noradrenaline (Norepinephrine)

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the **Disclaimer**.

Quick Links									
Dose	Administration	Monitoring	Pregnancy and Breastfeeding						
Restrictions									
Formulary: Unrestricted									
HIGH RISK Medication									
Medication Class									
Sympathomimetics (cardiovascular)									
Presentation									
Ampoule: 4mg/4mL (1:1000)									
Storage									
Store below 25°C. Protect from light.									
Dose									
Refer to Clinical Guideline: <u>Gynaecology (Non-oncological)</u>									
Administration									
Refer to Clinical Guideline: Gynaecology (Non-oncological)									
Monitoring									
Continuous cardiac monitoring is required Extravasation can cause tissue necrosis.									

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

Breastfeeding

Safe to use

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Gynaecology (Non-oncological)

References

Australian Medicines Handbook. Noradrenaline. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2021 Dec 17]. Available from: <u>https://amhonline.amh.net.au/</u>

Society of Hospital Pharmacists of Australia. Noradrenaline. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Dec 17]. Available from: <u>http://aidh.hcn.com.au</u>

The Royal Women's Hospital. Noradrenaline. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2021 Dec 17]. Available from: <u>https://thewomenspbmg.org.au/</u>

Keywords	Noradrenaline, Norepinephrine, vasoconstrictor, sympathomimetic (cardiovascular)							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	4.0							
Date First Issued:	31/01/2009	Last Reviewed:	21/12/2021		Review Date:	21/12/2024		
Endorsed by:	Medicines and Therapeutics Committee				Date:	01/03/2022		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management				
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.